TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33469316
Drug: Tezepelumab 70
Normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tezepelumab 70 mg Q4W
Study: 33469316
Drug: Tezepelumab 280
Normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tezepelumab 280 mg Q2W
Study: 33469328
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine biosimilar Ezelin (EZL)
Study: 33469328
Drug: Originator insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Originator insulin glargine Lantus (LAN)
Study: 33469351
Drug: Active low-level
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active low-level laser therapy + moderate-intensity aerobic exercise
Study: 33469351
Drug: Placebo low-level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo low-level laser therapy + moderate-intensity aerobic exercise
Study: 33469828
Drug: Persistently Gd-enhancing
Normalized name: Gd-HPDO3A
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Persistently Gd-enhancing lesions (PE group) in aquaporin-4-positive, first-attack, transverse myelitis or high-dose steroid treatment subgroup
Study: 33469852
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of autologous bone marrow-derived mesenchymal stem cells (MSCs) (1 × 10)
Study: 33470662
Drug: Minimizing time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimizing time to antimicrobial therapy
Study: 33470662
Drug: Appropriate antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate antibiotic choice
Study: 33470662
Drug: Antimicrobial dosing
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial dosing
Study: 33470662
Drug: De-escalation of
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-escalation of therapy
Study: 33470897
Drug: Aminolevulinic acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminolevulinic acid topical application and 633 nm red light illumination
Study: 33471949
Drug: docetaxel cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel cisplatin 5-fluorouracil induction chemotherapy
Study: 33472666
Drug: Axitinib 3
Normalized name: Axitinib 3 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 3 mg twice daily (MTD)
Study: 33472666
Drug: Axitinib 1
Normalized name: axitinib 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 1 mg twice daily
Study: 33472666
Drug: Axitinib 2
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib 2 mg twice daily
Study: 33472666
Drug: Axitinib 3
Normalized name: Axitinib 3 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axitinib 3 mg twice daily
Study: 33473101
Drug: Personalized neoantigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized neoantigen peptide-pulsed autologous dendritic cell vaccine
Study: 33474638
Drug: Energy-restricted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-restricted treatment
Study: 33474858
Drug: Aspirin provocation
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin provocation
Study: 33474858
Drug: Drug provocation
Normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug provocation
Study: 33474976
Drug: Initial hs-cTnT
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial hs-cTnT measures below the limit of quantification (LOQ: 6 ng/L)
Study: 33475793
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of 50 mg of hyperbaric prilocaine
Study: 33476432
Drug: Voxelotor treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voxelotor treatment, dosage and duration not available
Study: 33477665
Drug: Behavior related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior related to treatment of LUTS
Study: 33477964
Drug: Customized human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Customized human milk fortification using a multi-nutrient fortifier and modular supplements of protein and fat.
Study: 33477979
Drug: Cemiplimab (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemiplimab (monoclonal antibody targeting PD1), administered for ten cycles
Study: 33478647
Drug: Transcatheter treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter treatment of secondary tricuspid regurgitation
Study: 33478921
Drug: Carfilzomib in
Normalized name: carfilzomib Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib in combination with bendamustine and rituximab
Study: 33479501
Drug: NeoVax, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeoVax, a long-peptide vaccine targeting up to 20 personal neoantigens per patient
Study: 33479856
Drug: LY3295668 erbumine
Normalized name: Perindopril Erbumine
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LY3295668 erbumine 25 mg BID
Study: 33479856
Drug: LY3295668 erbumine
Normalized name: Perindopril Erbumine
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LY3295668 erbumine 50 mg BID
Study: 33479856
Drug: LY3295668 erbumine
Normalized name: Perindopril Erbumine
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LY3295668 erbumine 75 mg BID
Study: 33479856
Drug: LY3295668 erbumine
Normalized name: Perindopril Erbumine
DrugBank: Perindopril (DB00790)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LY3295668 erbumine (all doses)
Study: 33480607
Drug: Conservative physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative physical therapy (10 sessions)
Study: 33480608
Drug: Paracetamol (analgesic)
Normalized name: Analgesic Balm GRX
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (analgesic)
Study: 33480854
Drug: DMT app
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMT app assessing impulsivity in daily life
Study: 33481332
Drug: Prescribed light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed light exercise (30 minutes of daily light exercise)
Study: 33481403
Drug: Intraoperative methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative methadone (0.1 mg/kg, maximum 5 mg) and postoperative every 12 hours for 3-5 doses
Study: 33481672
Drug: Prior oral
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior oral contraceptive use
Study: 33481672
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no prior oral contraceptive use)
Study: 33483802
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine infusion (0.15 mg/kg/h titrated toward 0.6 mg/kg/h)
Study: 33484136
Drug: Maternal lutein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal lutein and zeaxanthin intake during pregnancy (mean daily intake: 2.6 mg)
Study: 33485301
Drug: EFV 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFV 400 mg combined with tenofovir (TDF) and lamivudine (3TC) for 48 weeks
Study: 33485708
Drug: Individualized food-based
Normalized name: food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized food-based nutrition intervention program (6 months duration, caloric restriction of 500-1000 kcal/d when applicable, protein intake of 1.2-1.5 g/kgBW/d, 5-9 servings/day of fruits and vegetables)
Study: 33485799
Drug: Imiglucerase treatment
Normalized name: Imiglucerase
DrugBank: Imiglucerase (DB00053)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiglucerase treatment
Study: 33486223
Drug: Daily egg
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily egg intake
Study: 33486971
Drug: Noninvasive ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive ultrasound therapy
Study: 33487029
Drug: Second-line antiretroviral
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line antiretroviral (ART) treatment
Study: 33487127
Drug: 1,25-dihydroxyvitamin D
Normalized name: 1,25-dihydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25-dihydroxyvitamin D (1,25(OH)D); specific dosage and duration not mentioned
Study: 33487279
Drug: Triheptanoin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triheptanoin treatment for 78 weeks
Study: 33487468
Drug: 1 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg CV7202
Study: 33487468
Drug: 2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg CV7202
Study: 33487468
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg CV7202
Study: 33487468
Drug: 1 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg CV7202 (after two doses)
Study: 33487468
Drug: 2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg CV7202 (after two doses)
Study: 33487824
Drug: Articaine 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine 2% (40 ml)
Study: 33487824
Drug: Articaine 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine 2% mixed with dexmedetomidine (1 μg.kg) (40 ml)
Study: 33488576
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Hiltonol and vaccine antigens only)
Study: 33489806
Drug: Treatment patterns
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment patterns (type/duration, number of lines, completion rate)
Study: 33489806
Drug: Early-stage treatment
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-stage treatment (starting from 1 December 2010)
Study: 33489806
Drug: Kaplan-Meier curves
Normalized name: meyer lemon extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaplan-Meier curves for treatment duration and overall survival
Study: 33490640
Drug: Mobile outreach
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile outreach team approach with oral anti-TB treatment under DOTS
Study: 33490640
Drug: Facility-based DOTS
Normalized name: D3 Dots
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facility-based DOTS treatment according to WHO recommendations
Study: 33490707
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative body radiotherapy (SABR) - 20Gy single fraction followed by pembrolizumab - 200 mg every 3 weeks for 8 cycles
Study: 35618285
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg) intravenously every 21 days
Study: 33491668
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) at a dosage of 1 × 10^6 to 3 × 10^6 cells/kg, administered as 3 injections every 2 weeks for 8-24 months.
Study: 33492239
Drug: Weekly subcutaneously
Normalized name: Weekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly subcutaneously administered methotrexate
Study: 33492239
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral azathioprine or 6-mercaptopurine
Study: 33492239
Drug: Subcutaneously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administered adalimumab (ADA)
Study: 33492438
Drug: AR-42, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-42, 60 mg three times weekly for 3 weeks of a 28-day cycle
Study: 33492986
Drug: Toripalimab 3
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab 3 mg/kg every 2 weeks via intravenous infusion until disease progression or unacceptable toxicity
Study: 33492986
Drug: Toripalimab 3
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab 3 mg/kg every 2 weeks via intravenous infusion
Study: 33493312
Drug: Intravenous golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous golimumab (80 mg/m2 at weeks 0, 4, then every 8 weeks through week 52 plus MTX weekly through week 28)
Study: 33493312
Drug: Intravenous golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous golimumab
Study: 33493392
Drug: Ivosidenib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivosidenib (100 mg twice daily and 300-1200 mg once daily)
Study: 33493590
Drug: Preoperative lymphocyte
Normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative lymphocyte count <0.6 (×10^9/L)
Study: 33493697
Drug: Direct acting
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct acting antiviral agents (DAAs) leading to sustained virologic response (SVR)
Study: 33493822
Drug: Apraxia of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apraxia of Speech Rating Scale (ASRS) administered by five speech-language pathologists (SLPs)
Study: 33494963
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose recombinant full-length circumsporozoite protein-based vaccine with GLA-LSQ adjuvant
Study: 33495312
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (ATRA) plus tranylcypromine (TCP) at three dose levels: 10 mg twice daily, 20 mg twice daily, and 30 mg twice daily.
Study: 33495476
Drug: Prior treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior treatments
Study: 33495752
Drug: Ivermectin 400
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 400 mcg/kg, single dose
Study: 35244520
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg every 2 weeks for up to 2 years
Study: 33496677
Drug: Fitbit Zip
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fitbit Zip activity tracker worn daily for 8 weeks (2 weeks prior to surgery and 6 weeks post-surgery)
Study: 33496747
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg daily for 14 days per cycle combined with 8 cycles of CHOP21
Study: 33496906
Drug: Fluid challenge
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid challenge (500 mL gelatin over 15 min)
Study: 33498797
Drug: Palbociclib +
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib + Letrozole (P+L)
Study: 33501400
Drug: 6 weekly
Normalized name: tobramycin 28 MG inhalation powder 56 Weekly Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 weekly doses of lyophilized fecal microbiota product from healthy donors
Study: 33502111
Drug: Oral tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tacrolimus (0.03 mg/kg) administered twice daily starting 3 days prior to transplant
Study: 33502111
Drug: Dosing simulation
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing simulation strategy based on observed tacrolimus concentration
Study: 33502567
Drug: Ultra-Low Doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-Low Doses of Therapy with Radiation (ULTRA-COVID)
Study: 33503046
Drug: Increased PPI
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased PPI doses or use of PPIs not metabolized by CYP2C19 (rabeprazole)
Study: 33503342
Drug: Levonorgestrel IUD
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel IUD (52-mg)
Study: 33505715
Drug: Conjunctival autografting
Normalized name: Sus scrofa conjunctiva preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjunctival autografting augmented with topical application of MMC (0.2 mg/mL)
Study: 33505726
Drug: 2 l/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 l/min supplemental oxygen during bronchoscopy
Study: 33505726
Drug: No oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oxygen administration during bronchoscopy
Study: 33506177
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment (G1)
Study: 33506571
Drug: Capmatinib 400
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib 400 mg twice daily
Study: 33506635
Drug: Molidustat (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molidustat (75 mg once daily, adjusted to maintain Hb target of ≥10.0 to <12.0 g/dL)
Study: 33506635
Drug: Molidustat (dose-titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molidustat (dose-titrated for 24 weeks)
Study: 33507454
Drug: Mavorixafor 400
Normalized name: Mavorixafor
DrugBank: Mavorixafor (DB05501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavorixafor 400 mg daily plus nivolumab 240 mg every 2 weeks
Study: 33507604
Drug: Vincristine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine and topotecan (VT) neoadjuvant intravenous chemotherapy
Study: 33507803
Drug: Autologous T-cell
Normalized name: an autologous T-cell immunotherapy (ET140203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous T-cell product targeting multiple tumor-associated antigens (TAAs) including PRAME, SSX2, MAGEA4, SURVIVIN, and NY-ESO-1, administered at a fixed dose of 0.5 × 10^6 T cells, with a maximum tested dose of two infusions of 2 × 10^6 T cells
Study: 33507822
Drug: Mirdametinib (PD-0325901)
Normalized name: Mirdametinib
DrugBank: Mirdametinib (DB07101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirdametinib (PD-0325901) at 2 mg/m, administered by mouth twice a day
Study: 33508475
Drug: Modified Duke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Duke criteria, heart murmur, and intensive care therapy
Study: 33509135
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT), 10 sessions as part of normal clinical management.
Study: 33512057
Drug: 7-day ECG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day ECG patch monitor
Study: 33512323
Drug: Therapist-guided online
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-guided online therapy (1 session per week for 6 weeks, utilizing cognitive behavioral therapy and acceptance and commitment therapy)
Study: 33512323
Drug: Self-help internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help internet-based therapy (automatic weekly newsletter with self-help information and tips)
Study: 33512323
Drug: Therapist-guided online
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-guided online therapy
Study: 33512323
Drug: Self-help internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help internet-based therapy
Study: 33512414
Drug: CAR22 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAR22 therapy (1 × 10^6 CAR+ T cells per kilogram targeting CD22)
Study: 33512414
Drug: CAR22 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAR22 therapy
Study: 33512441
Drug: ≥1 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: ≥1 injection per week (18.1% of patients, n=37)
Study: 33512441
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment (16.6% of patients, n=34)
Study: 33512452
Drug: VLS-101 (antibody-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: VLS-101 (antibody-drug conjugate targeting ROR1)
Study: 33512666
Drug: Risankizumab 90
Normalized name: Risankizumab 90.361 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 90 or 180 mg every 12 weeks for at least 48 weeks
Study: 33512794
Drug: MOWOOT device
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOWOOT device (intermittent colonic exo-peristalsis) used daily for 20 minutes over 4 weeks
Study: 33513372
Drug: MATRix-RICE (rituximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: MATRix-RICE (rituximab 375 mg/m2) plus autologous HSCT
Study: 34794172
Drug: Hypomethylating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypomethylating agents
Study: 33513645
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone supplementation
Study: 33514524
Drug: LY3321367 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3321367 with LY300054 (anti-PD-L1 antibody)
Study: 33516248
Drug: Cluster analysis
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster analysis of biological markers
Study: 36395989
Drug: Vortioxetine 10-20
Normalized name: vortioxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine 10-20 mg/day for 8 weeks
Study: 33516721
Drug: Idelalisib interruption
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idelalisib interruption after ≥ 6 months of treatment
Study: 33516721
Drug: Idelalisib interruption
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idelalisib interruption with dose reduction
Study: 33516721
Drug: Time off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time off therapy of ≥ 8%
Study: 33517043
Drug: Radiotherapy (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (conventional fractionation and hypofractionation); dose range: 43.4 to 71.0 Gy (median dose: 48.6 Gy); boost radiation therapy administered to 49 patients.